ストックスクリーナーアプリを入手
21.49
14.37%
-3.6072
前日終値:
$25.10
開ける：
$24.17
24時間の取引高:
5.90M
Relative Volume:
1.93
時価総額：
$1.81B
収益：
-
当期純損益:
$-27.03M
株価収益率:
-38.38
EPS:
-0.56
ネットキャッシュフロー:
$-23.97M
1週間 パフォーマンス:
+167.00%
1か月 パフォーマンス:
+179.13%
6か月 パフォーマンス:
+356.33%
1年 パフォーマンス:
+307.07%
1日の値動き範囲:
$20.70
$24.41
1週間の範囲:
$12.69
$26.95
52週間の値動き範囲:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
863 MITTEN ROAD, BURLINGAME, CA
CRVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
21.61 | 2.10B | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.26 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.25 | 79.20B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.17 | 50.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.83 | 47.29B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
337.77 | 37.55B | 4.98B | 69.59M | 525.67M | 0.5197 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study - Finviz
Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans - Yahoo Finance
What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc? - Sahm
Corvus Pharmaceuticals raises $201.2 million in upsized public offering By Investing.com - Investing.com South Africa
Corvus rally continues as clinical optimism offsets dilution concerns - Mugglehead Magazine
Corvus Pharmaceuticals raises $201.2 million in upsized public offering - Investing.com
Corvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 Million - Quiver Quantitative
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - The Manila Times
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - GlobeNewswire Inc.
Cantor Fitzgerald reiterates Overweight rating on Corvus Pharmaceuticals stock By Investing.com - Investing.com Canada
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results - Finviz
Corvus Pharmaceuticals - The Pharma Letter
Corvus Pharmaceuticals Announces Major Underwritten Public Stock Offering - TipRanks
Corvus Pharmaceuticals Announces Public Offering of Common Stock - TradingView
Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains - MarketBeat
10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Are Hitting New Highs - Insider Monkey
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap UpHere's What Happened - MarketBeat
Jefferies raises Corvus Pharmaceuticals stock price target to $42 on strong AD data - Investing.com Canada
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Corvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15 - MSN
Corvus Pharmaceuticals Prices Upsized Public Stock Offering - Eudaimonia and Co
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals launches $150 million public offering By Investing.com - Investing.com India
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials - Intellectia AI
Corvus Pharmaceuticals prices upsized public offering at $22.15 per share - Investing.com
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Yahoo Finance
Corvus Pharmaceuticals Announces Pricing of Upsized Underwritten Public Offering of Common Stock - Quiver Quantitative
Corvus Pharma raises $175M to advance lymphoma and atopic dermatitis trials - Stock Titan
Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer - TipRanks
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon (CRVS) - Seeking Alpha
Corvus Pharmaceuticals stock hits all-time high at 22.22 USD - Investing.com
Smart Money Is Betting Big In CRVS Options - Benzinga
Corvus Pharmaceuticals stock (CRVS) swings as $150M share sale follows eczema-data surge - TechStock²
Corvus Pharmaceuticals slides premarket after unveiling $150M equity raise - MSN
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know (CRVS) - Seeking Alpha
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Corvus Pharmaceuticals (CRVS) Is Up 229.4% After Strong Soquelitinib Data In Tough Dermatitis Patients - simplywall.st
Corvus Pharmaceuticals stock price target raised to $27 from $11 at H.C. Wainwright - Investing.com Canada
Corvus Pharmaceuticals Stock (CRVS) Opinions on Phase 1 Trial Results - Quiver Quantitative
Corvus Pharmaceuticals stock price target raised to $27 from $11 at H.C. Wainwright By Investing.com - Investing.com Australia
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Corvus Pharmaceuticals Stock Pre-Market (-5.9%): Announces $150M Public Offering - Trefis
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge - TechStock²
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Corvus Pharmaceuticals shares fall after announcing $150 million stock offering - Investing.com
Corvus Pharma Commences Public Offering Of $150 Mln Of Shares; Stock Down - Nasdaq
Corvus reports positive phase 1 data for atopic dermatitis drug By Investing.com - Investing.com India
Corvus Pharma stock dips over 6% after-hours following best day ever — what went wrong? - MSN
Corvus Pharmaceuticals Launches $150 Million Public Offering to Fund Clinical Trials - Intellectia AI
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Positive Soquelitinib Phase 1 Atopic Dermatitis Data - Yahoo Finance
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? - Stocktwits
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
16.66%
0.60%
大文字化:
|
ボリューム (24 時間):